RNA Technologies Enabling Drug Discovery and Development

1.1 Research Scope: RNA Therapies Redefining the Healthcare Landscape

1.2 Analysis Framework: Frost & Sullivan’s Core Value

1.3 Research Methodology: Five Steps Towards Success

1.4 Key Findings

2.1 RNA is the Rising Star of Transformative Therapy Platforms

2.2 Industry Accelerators and Challenges

2.3 RNA Delivery: Technology Segmentation

2.4 RNA Therapies: Technology Segmentation

2.5 Molecular Insights Across RNA Therapy

3.1 Alternative Splicing Induced by SSO Therapies

3.2 Clinical Pipeline Analysis for SSO Therapies for SMA and DMD

3.3 Post-transcriptional Modifications by ASO

3.4 Clinical Pipeline Overview for ASO Therapies

3.5 Emerging Clinical Pipeline for ASO Therapies

3.6 Early Phase ASO Therapies

3.7 Inhibition of Ligand Binding by Aptamer

3.8 Clinical Pipeline Analysis for Aptamer Therapies

3.9 Landmark Year for RNA Interference Therapy Platform

3.10 Clinical Analysis of RNA Interference Therapeutics

3.11 Overview of the Emerging Landscape for mRNA Therapies

3.12 Clinical Pipeline Analysis of mRNA Therapies

3.13 saRNA: The Rising Participant in RNA-based Therapies

4.1 Patenting Trends for ASO Technologies

4.2 Patenting Trends for RNAi Platforms

4.3 Patenting Trends for mRNA Technologies

5.1 Targeted RNAi Technology for Enhanced Disease Management

5.2 Enabling Targeted Delivery of RNAi Therapeutics

5.3 Developing Stable and Non-immunogenic mRNA Therapies

5.4 Fueling Novel RNA Therapy and Delivery Platforms

5.5 Enabling Potent Antisense Therapeutics

6.1 RNA Platforms likely to Transform the Future of Health & Wellness

6.2 Navigating Through The Future Landscape for RNA Technologies

7.1 Growth Opportunity 1: ASO Therapies

7.2 Growth Opportunity 2: RNAi Therapies

7.3 Growth Opportunity 3: mRNA Therapies

7.4 Strategic Imperatives for Success and Growth

8.1 Industry Interactions

8.1 Industry Interactions (continued)

Legal Disclaimer